Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

submitted for approval for hepatocellular carcinoma, a form of liver cancer. ... A second cohort of endometrial cancer patients had an ORR of 52% at the same timepoint.

Latest news

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    The company’s programmes are still in preclinical development and include projects in prostate cancer, liver cancer and multiple myeloma. ... It’s an exciting time, ”said Renier Brentjens, medical oncologist and director of cellular therapeutics at

  • Dynavax receives FDA green light for hepatitis B vaccine Dynavax receives FDA green light for hepatitis B vaccine

    Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death.

  • Ipsen’s liver cancer treatment clears phase III trial Ipsen’s liver cancer treatment clears phase III trial

    Ipsen’ s liver cancer treatment clears phase III trial. Cabometyx on track for new liver cancer indication. ... s chief scientific officer, said: “Liver cancer is one of the leading causes of cancer deaths worldwide and more effective treatment

  • Keytruda adds stomach cancer to growing list of US approvals Keytruda adds stomach cancer to growing list of US approvals

    Keytruda adds stomach cancer to growing list of US approvals. FDA clears the drug as a third-line option after chemotherapy. ... Opdivo has also just picked up a US approval as a second-line treatment for hepatocellular carcinoma - a common form of liver

More from news
Approximately 9 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Much like its work in liver cancer with Cabometyx, being active in pancreatic cancer allows it to compete in less crowded areas, a tacit acknowledgement that, for now, it lacks the ... We try to [focus on] pancreas, liver and bladder cancer, where there

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... This protracted process is indicative of the now

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics